tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sykes, 70 are a HOLD (33.33%), 33 are a SELL (15.71%), 107 are a BUY (50.95%).
Analyst Matthew Sykes, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 57.65% that have a potential upside of 21.04% achieved within 88 days.
Matthew Sykes’s has documented 392 price targets and ratings displayed on 36 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on TXG, 10X Genomics at 12-May-2025.
Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$215
$0.01 (0.00%)
$240
5 months 19 days ago
(21-Apr-2025)
12/18 (66.67%)
$23.57 (12.31%)
281
Buy
$230
$15.01 (6.98%)
$240
5 months 19 days ago
(21-Apr-2025)
8/12 (66.67%)
$38.57 (20.15%)
436
Buy
$260
$45.01 (20.94%)
$250
6 months 20 days ago
(20-Mar-2025)
4/6 (66.67%)
$49.67 (23.62%)
88
Hold
$260
$45.01 (20.94%)
$265
8 months 11 days ago
(29-Jan-2025)
5/7 (71.43%)
$38.01 (17.12%)
183
Buy
$265
$50.01 (23.26%)
$270
8 months 12 days ago
(28-Jan-2025)
2/3 (66.67%)
$42.36 (19.03%)
99
Which stock is Matthew Sykes is most bullish on?
Which stock is Matthew Sykes is most reserved on?
What Year was the first public recommendation made by Matthew Sykes?
